# US 2010/0167993 A1 · Compounds for Enhancing p21 Expression and Methods of Use Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0167993 A1
- Document ID: US20100167993A1
- Status: Published application
- Kind: A1
- Application number: 12/663,091
- Filed: 2008-06-05
- Published: 2010-07-01
- Earliest claimed: 2007-06-05
- Assignees: Cornell University
- Inventors: Rajiv R. Ratan; Brett C. Langley; Brian S. Ko
- Web page: https://patentgrep.com/patent/US20100167993A1

## CPC

- C07K 14/4738: {Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR (cell cycle dependent kinases C12N9/12)}
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/12: Antidiuretics, e.g. drugs for diabetes insipidus (ADH A61P5/10)
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- G01N 33/5041: {involving analysis of members of signalling pathways}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to a method for identifying a drug candidate for enhancing expression of p21ctpl/wafl in a human patient suffering from a medical condition that can be treated by enhancing expression of p21Cφl/wafl. The method includes (a) providing a cell line comprising a nucleic acid sequence that comprises a p21ctpl/wafl promoter operationally ligated to a reporter domain; (b) exposing the cell line to a compound; and (c) identifying a compound that induces expression of the reporter domain. The compound that induces expression of the reporter domain is a drug candidate for treating a medical condition that can be treated by enhancing expression of p21cipl/wafl.

## Claims

### Claim 1

A method for identifying a drug candidate for enhancing expression of p21cipl/wafl in a human patient suffering from a medical condition that can be treated by enhancing expression of p21cipl/wafl, the method comprising:
(a) providing a cell line comprising a nucleic acid sequence that comprises a p21cipl/wafl promoter operationally ligated to a reporter domain;
(b) exposing the cell line to a compound; and
(c) identifying a compound that induces expression of the reporter domain;
wherein the compound that induces expression of the reporter domain is a drug candidate for treating a medical condition that can be treated by enhancing expression of p21cipl/wafl.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the medical condition can be treated by inhibiting cell cycle progression.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the medical condition is spinal cord injury.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the medical condition is stroke, trauma, or insult to the central nervous system.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the medical condition is a neurodegenerative disease.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the cell line is a human hippocampal cell line.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the reporter domain expresses luciferase.

### Claim 8

A method for enhancing expression of p21cipl/wafl in a human patient suffering from a medical condition that can be treated by enhancing expression of p21cipl/wafl, the method comprising administering to the patient an effective amount of a compound selected from the group consisting of ciclopirox olamine, dihydrocelastrol, colistimethate sodium, lycorine, diphenylurea, and acetylcysteine, chloroquine diphosphate, and 4′-methoxyflavone (acacetin).

### Claim 9 (depends on 8)

The method according to claim 8, wherein the compound is selected from the group consisting of ciclopirox olamine, dihydrocelastrol, colistimethate sodium, lycorine, diphenylurea, and acetylcysteine.

### Claim 10 (depends on 8)

The method according to claim 8, wherein the compound is selected from the group consisting of chloroquine diphosphate and 4′-methoxyflavone (acacetin).

### Claim 11 (depends on 8)

The method according to claim 8, wherein the medical condition is spinal cord injury.

### Claim 12 (depends on 8)

The method according to claim 8, wherein the medical condition is stroke, trauma, or insult to the central nervous system.

### Claim 13 (depends on 8)

The method according to claim 8, wherein the medical condition is a neurodegenerative disease.

### Claim 14 (depends on 8)

The method according to claim 8, wherein the neurodegenerative disease is Parkinson's disease, Alzheimer's disease, Huntington's disease or amyotrophic lateral sclerosis (also known as Lou Gherig's disease).

### Claim 15 (depends on 8)

The method according to claim 8, wherein the compound is selected from the group consisting of ciclopirox olamine, dihydrocelastrol, colistimethate sodium, lycorine, diphenylurea, and acetylcysteine.

### Claim 16 (depends on 8)

The method according to claim 8, wherein the compound is ciclopirox olamine.

### Claim 17 (depends on 8)

The method according to claim 8, wherein the compound is dihydrocelastrol.

### Claim 18 (depends on 8)

The method according to claim 8, wherein the compound is chloroquine diphosphate.

### Claim 19 (depends on 8)

The method according to claim 8, wherein the compound is colistimethate sodium.

### Claim 20 (depends on 8)

The method according to claim 8, wherein the compound is lycorine.

### Claim 21 (depends on 8)

The method according to claim 8, wherein the compound is 4′-methoxyflavone (acacetin)

### Claim 22 (depends on 8)

The method according to claim 8, wherein the compound is diphenylurea.

### Claim 23 (depends on 8)

The method according to claim 8, wherein the compound is acetylcysteine.
